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Abstract
Monoamine oxidase B (MAO-B) inhibitors have an established role in the treatment of Parkinson’s disease as monotherapy 
or adjuvant to levodopa. Two major recognitions were required for their introduction into this therapeutic field. The first was 
the elucidation of the novel pharmacological properties of selegiline as a selective MAO-B inhibitor by Knoll and Magyar 
and the original idea of Riederer and Youdim, supported by Birkmayer, to explore its effect in parkinsonian patients with 
on–off phases. In the 1960s, MAO inhibitors were mainly studied as potential antidepressants, but Birkmayer found that 
combined use of levodopa and various MAO inhibitors improved akinesia in Parkinson’s disease. However, the serious 
side effects of the first non-selective MAO inhibitors prevented their further use. Later studies demonstrated that MAO-B, 
mainly located in glial cells, is important for dopamine metabolism in the brain. Recently, cell and molecular studies revealed 
interesting properties of selegiline opening new possibilities for neuroprotective mechanisms and a disease-modifying effect 
of MAO-B inhibitors.
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Abbreviations
ADL  Activity of daily living
MAO  Monoamine oxidase
ODT  Orally disintegrating tablets
PD  Parkinson’s disease
STS  Selegiline transdermal system
UPDRS  Unified Parkinson’s disease rating scale
History
The story of the monoamine oxidase B (MAO-B) inhibi-
tors started with the discovery of selegiline (R-deprenyl). 
The compound was synthesized by Zoltán Ecseri in Chinoin 
Pharmaceuticals (Budapest, Hungary) in 1962 along with a 
series of similar, structurally related drug candidates. Their 
pharmacology was thoroughly studied in the laboratories of 
Joseph Knoll at Semmelweis University (Budapest, Hun-
gary) (Knoll and Magyar 1972; Magyar et al. 1979; Knoll 
1979). They were looking for psychic energizers based on 
the known antidepressant effect of MAO inhibitors (Knoll 
et al. 1965). The first clinical study was performed accord-
ing to this intended indication (Varga and Tringer 1967). 
However, Knoll and Magyar observed peculiar features 
of deprenyl different from those of previously used MAO 
inhibitors, e.g., it lowers blood pressure and is free from 
“cheese effect”, the severe drug–food interaction of irre-
versible MAO inhibitor antidepressants. Namely, severe 
hypertensive crisis can develop when food rich in tyramine 
is consumed by patients treated by these drugs [for review 
see Finberg and Gillman (2011)]. The selective inhibitory 
effect of selegiline on one of the MAO isoforms was identi-
fied by Knoll and Magyar (1972). Parallel to their observa-
tion, Johnston published that the MAO enzyme exists in two 
distinct isoforms based on selective inhibition of one of them 
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by clorgyline, which was named MAO-A (Johnston 1968). 
Selegiline, however, inhibits irreversibly the other isoform, 
and this was assigned as MAO-B. The other observation 
of Magyar was that the levorotatory isomer of the chiral 
deprenyl, R-deprenyl later called selegiline is a more potent 
inhibitor of MAO-B and has better pharmacological profile 
compared to the other deprenyl enantiomer (Magyar et al. 
1967; Knoll and Magyar 1972).
The two MAO isoforms can be distinguished not only by 
their selective inhibitors, but they differ in their substrate 
specificity, as well. Serotonin and noradrenaline are specific 
substrates of MAO-A explaining the antidepressant and 
blood pressure increasing effects of its inhibitors (Finberg 
and Youdim 1983). β-Phenylethylamine was first identi-
fied as MAO-B substrate, since the selective inhibition of 
MAO-B increased the level of this biogenic amine (Reynolds 
et al. 1978). Only later on was it revealed that dopamine is 
also a substrate of MAO-B (Glover et al. 1977). Actually, 
it was shown to be a substrate of both MAO isoenzymes 
(O’Carroll et al. 1983).
It was the idea of one of us (P. R.) that an MAO inhibi-
tor with favorable side effect profile was worth trying to 
treat Parkinson’s disease (PD) patients to prevent the serious 
on–off phenomenon. This suggestion was based on the clini-
cal observations of Birkmayer and Hornykiewicz in the early 
1960s that various MAO inhibitors provided mild clinical 
benefits in the treatment of PD (Birkmayer and Hornykie-
wicz 1962). However, the potential hypertensive effect of 
the non-selective irreversible MAO inhibitors restricted 
their further use. M. Y. informed P. R. about the new selec-
tive MAO-B inhibitor compound, selegiline, free from the 
“cheese effect” and without liver toxicity, which is another 
problem with some irreversible MAO inhibitors. Although 
at that time they were not aware that dopamine was a good 
substrate of MAO-B, furthermore based on rodent studies 
it was rather regarded as a MAO-A substrate, after some 
debate P. R., M. Y. and Birkmayer finally concluded that 
selegiline was worth trying in PD. M. Y. had got some sele-
giline from Knoll for experimental works and he provided 
it for starting to treat parkinsonian patients in 1974. The 
benefit of the treatment with the combination of levodopa 
and selegiline was first published in 1975 (Birkmayer et al. 
1975) and 2 years later its long-term effectiveness was also 
reported (Birkmayer et al. 1977).
Later on, human post-mortem brain studies revealed that 
MAO-B isoform was present in the human brain, predomi-
nantly in glia (Konradi et al. 1989; Riederer et al. 1987; 
Collins et al. 1970). In various regions of post-mortem brain 
of selegiline-treated patients, elevated β-phenylethylamine 
and dopamine levels were detected (Riederer et al. 1984; 
Riederer and Youdim 1986), supporting the dopamine-
sparing effect of the MAO-B inhibition, which is in line 
with the clinical findings. Platelet MAO-B inhibition in 
selegiline-treated patients was also demonstrated (Riederer 
et al. 1978).
On the proposal of two of us (P. R. and M. Y.) data from 
PD patients treated for a long time with selegiline in the 
Lainz Geriatric Hospital, Vienna, were analyzed. The inter-
esting results demonstrated a prolongation of life expec-
tancy for selegiline-treated PD patients first published in 
1983 (Birkmayer 1983). The re-analysis of the data by 
more sophisticated statistical methods showed the same 
result (Birkmayer et al. 1985). These publications gave a 
new impetus on preclinical and clinical studies on selegiline 
aiming at elucidation of its possible neuroprotective effect.
Experimental data from numerous animal and cell culture 
studies provided evidence that selegiline protects against 
various neurotoxins, reduces oxidative stress and possesses 
neurotrophic and antiapoptotic effects. All these properties 
may contribute to its neuroprotective activity. These preclin-
ical findings were previously thoroughly reviewed (Gerlach 
et al. 1996; Magyar et al. 2004, 2006; Naoi and Maruyama 
2010; Maruyama and Naoi 2013; Szoko et al. 2018).
Clinical studies on selegiline in PD
The increasing amount of preclinical pharmacological data 
about the possible neuroprotective effect of selegiline raised 
the hypothesis that it may slow the progression of PD. To 
prove this concept, several placebo-controlled randomized 
clinical trials were initiated from the late 1980s. A smaller 
study of 54 patients published in 1989 was the first report-
ing that 10 mg/day selegiline treatment delayed the need for 
levodopa therapy by about 8 months, which was ascribed 
to a possible disease progression-slowing effect (Tetrud 
and Langston 1989). However, it was immediately debated 
because the bare symptomatic effect of selegiline result-
ing from its dopamine-sparing effect could not be ruled out 
(Friedhoff 1990). The first large-scale multicenter controlled 
clinical trial was initiated in 1987 and it also aimed at deter-
mining the disease-modifying effect of selegiline in early 
PD, which was supposed to be related to the recognized 
antioxidant property of MAO inhibition. Hydrogen peroxide 
is one of the products of MAO-catalyzed amine oxidation 
reaction and it can be converted to further reactive oxygen 
species resulting in cytotoxicity. The inhibition of MAO 
activity thus may reduce oxidative stress. As the putative 
mechanism of neuroprotection was the antioxidant prop-
erty of selegiline, another antioxidant, tocopherol, was also 
included in the study in addition to placebo as comparator. 
Eight hundred untreated PD patients were enrolled into this 
DATATOP study with primary end point of development of 
disability, necessitating the introduction of levodopa treat-
ment. In the interim reports evaluating the first 12 months of 
the trial, a 57% reduction in the number of subjects reaching 
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the primary end point was shown (Parkinson Study Group 
1989) and 50% less patients had to give up full-time employ-
ment (Shoulson 1992) in the 10 mg/day selegiline-treated 
group. The final report was based on the results of a mean 
14 ± 6 months treatment period. Selegiline therapy delayed 
the time to end point, the need of levodopa treatment, by 
about 9  months while tocopherol was ineffective. The 
mechanism of this beneficial effect was not revealed in the 
study, but the importance of the antioxidant property was 
questioned. Regarding symptoms control, assessed by Uni-
fied PD Rating Scale (UPDRS) and Activity of Daily Liv-
ing (ADL) scores, selegiline was most effective in the first 
3 months of the therapy. However, 2 months after its with-
drawal, the motor performance of patients declined (Parkin-
son Study Group 1993). These findings clearly indicate the 
symptomatic benefit of selegiline treatment, but its disease-
modifying effect was not unequivocally proven. In a continu-
ation of the study, selegiline was administered to all patients 
who did not reach the primary end point over 21 ± 4 months 
of observation. There was no significant difference between 
the previously selegiline- or placebo-treated groups in the 
time reaching the end point, the need of starting levodopa. 
The conclusion of the Parkinson Study Group was that the 
initial benefit of selegiline treatment was not sustained (Par-
kinson Study Group 1996). In another continuation, those 
selegiline-treated patients who required levodopa were re-
randomized after 5 years to continue selegiline or change 
to placebo. During the 2 years follow-up, there was no sig-
nificant difference in combined end points of development 
of wearing-off, dyskinesia and on–off fluctuation between 
the treatment groups. However, assessing the distinct motor 
disturbances, there were less freezing of gait, wearing-off 
and on–off fluctuation, but more dyskinesia in the selegiline 
group, which is consistent with its dopamine-potentiating 
effect (Shoulson et al. 2002). Further smaller studies were 
also performed to evaluate the advantage of selegiline mono-
therapy in early PD. Rapid improvement in several parkin-
sonian symptoms was demonstrated in several short-term 
studies (Allain et al. 1993; Mally et al. 1995). Some other 
trials, similarly to DATATOP study, aimed at evaluation of 
disease-modifying effect of selegiline. In the Finnish study 
54 untreated patients were randomized to 10 mg/day sele-
giline or placebo. The median time to initiation of levodopa 
treatment was found about 6 months longer (Myllyla et al. 
1991) and the necessary dose of levodopa for the sufficient 
therapeutic effect was about half in the selegiline group 
(Myllyla et al. 1993). The levodopa dose-sparing effect 
was not only maintained, but further increased after the 
5-year follow-up period. Selegiline treatment also reduced 
the need of additional dopaminergic therapy (slow release 
levodopa or dopamine agonist) (Myllyla et al. 1997). In a 
Swedish study of 157 early PD patients, selegiline signifi-
cantly delayed the need to start levodopa therapy by about 
4 months compared to placebo. Furthermore, the advantage 
of selegiline treatment in UPDRS scores was maintained 
after 2 months washout period before levodopa was started 
suggesting its neuroprotective effect (Palhagen et al. 1998). 
In the continuation of this study, the advantage of selegiline 
was also maintained after levodopa was started. Patients 
after 5 years on selegiline and levodopa combination had 
nearly ten points lower UPDRS scores, while 19% lower 
levodopa dose was used compared to levodopa only group 
(Palhagen et al. 2006). Recently, the benefit of selegiline 
monotherapy in early PD was also confirmed in a 12-week 
controlled trial in Japan, further supporting the use of the 
drug in early Parkinsonism (Mizuno et al. 2017).
These clinical trials unequivocally proved the efficacy of 
selegiline monotherapy in early PD (Table 1). In addition to 
symptoms improvement, it delays the introduction of levo-
dopa by 3–9 months and reduces the necessary levodopa 
dose. Some of the studies also indicate the long-term main-
tenance of the initial benefit, suggesting neuroprotective 
effect of early started selegiline treatment.
In addition to the continuations of monotherapy trials, 
combinational therapy studies were performed, as well. In 
the first double-blind randomized trial, 112 patients poorly 
responding to levodopa were subjected to 7.5 mg/day sele-
giline or placebo combination therapy. After 8 weeks, sig-
nificantly more patients showed moderate or better improve-
ment when selegiline was added to levodopa (Takahashi 
et al. 1994). Olanow et al. compared the deterioration of 
early PD patients receiving levodopa/carbidopa with or 
without selegiline combination for 12 months, followed by 
2 months selegiline washout period. The UPDRS score was 
deteriorated by 5.8 ± 1.4 points in the levodopa/carbidopa 
group, but remained unaltered (0.4 ± 1.3 point deteriora-
tion) in the levodopa/carbidopa + selegiline group. Because 
of the 2 months selegiline washout before the evaluation, 
these data suggest its disease-modifying rather than barely 
symptomatic effect (Olanow et al. 1995). Later on, the study 
design was criticized because there were no placebo and 
selegiline only groups. However, according to the authors’ 
answer, for demonstration of benefit of add-on selegiline 
treatment, the presented design was appropriate (Schulzer 
1997). The long-term benefit of addition of selegiline to 
levodopa treatment was reported by the Norwegian–Danish 
study group, as well. In the randomized placebo-controlled 
double-blind trial, combination treatment was continued 
for 5 years followed by 1-month selegiline washout. At the 
end of the study, symptoms were less severe and levodopa 
dose was lower when selegiline was combined to levodopa/
benserazide and no symptom worsening was observed after 
the washout period (Larsen et al. 1999). SELEDO trial 
evaluated the long-term outcome of early started combi-
nation treatment of levodopa with selegiline or placebo in 
160 patients. The primary end point was the need of more 
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than 50% increase in levodopa dose for symptoms control. 
Almost twice longer time (4.9 vs. 2.6 years) was needed 
to reach the end point in the selegiline combination group 
(Przuntek et al. 1999).
In addition to prospective studies, retrospective analysis 
of patient registers was also performed with contradictory 
results in terms of effect on disease progression. In one of 
the early reports, no significant difference between sele-
giline + levodopa and levodopa alone groups was found 
regarding Hoehn–Yahr stage and motor symptoms in a 
period of 5 years. The levodopa dose, however, was lower 
in case of the combination treatment (Brannan and Yahr 
1995). The benefit of long-term and/or early started sele-
giline treatment is indicated by other retrospective data 
analyses. Mizuno et al. reported that patients on combina-
tion of levodopa and selegiline had lower UPDRS scores 
compared to levodopa only treated group after about 
10 years of disease duration. Adding selegiline to levodopa 
at this time point, the UPDRS score, although improved 
after the 4-month combination treatment, did not reach the 
level seen in patients on early started combination therapy 
(Mizuno et al. 2010). Another study evaluated the factors 
affecting disease progression in 687 patients assessing the 
retardation of Hoehn–Yahr stage transition time. It was 
found that in early PD, at least 3-year selegiline treatment 
increased the transition times from stage 2 to 2.5 and 2.5 
to 3 (Zhao et al. 2011). Table 2 summarizes the results of 
studies on combinational therapies.
Contrary to the increased life expectancy of selegiline-
treated PD patients in the early observations of Birkmayer 
(1983) and Birkmayer et al. (1985), the Parkinson’s Dis-
ease Research Group of the UK reported increased mortal-
ity of patients treated with selegiline in combination with 
levodopa compared to levodopa alone during 5–7 years 
of follow-up (Lees 1995; Ben-Shlomo et al. 1998). How-
ever, meta-analyses of the available clinical trials with 
selegiline or any MAO-B inhibitors found no increase in 
mortality (Olanow et al. 1998; Ives et al. 2004; Macleod 
et al. 2005).
Based on the favorable effects of selegiline in PD, 
another irreversible MAO-B inhibitor, rasagiline, was 
introduced into the therapy. It was patented in 1995 (You-
dim et al. 1995). Interestingly its methylated derivative, 
J-508, has already been tested in Knoll’s laboratory for 
MAO inhibition in the 1970s and was found to be slightly 
more potent in vivo compared to selegiline (Knoll et al. 
1978). The pharmacological properties of rasagiline have 
been described by one of us (M. Y.). Its MAO inhibitory 
potential and selectivity in vitro are similar to those of 
selegiline, but in vivo it is about five times more potent 
Table 1  Clinical trials evaluating the effect of selegiline monotherapy in early PD
Design, number of patients (study 
name)
Studied daily dose Key findings References
Double-blind RCT, 54 patients 10 mg selegiline vs. placebo 8 months delay in the need of initiation 
of levodopa therapy
Tetrud and Langston (1989)
Double-blind RCT, 800 patients 
(DATATOP—Interim report)
10 mg selegiline vs. placebo 57% reduction in the number of 
patients needing levodopa after 
12 months treatment
Parkinson Study Group 
(1989), Shoulson (1992)
Double-blind RCT, 54 patients 10 mg selegiline vs. placebo 6 months delay in the need of initiation 
of levodopa therapy.
About half dose levodopa was needed 
in the selegiline group
Myllyla et al. (1991)
Myllyla et al. (1993)
Double-blind RCT, 93 patients 10 mg selegiline vs. placebo Improved motor rating and depressive 
scores after 3 months in the selegiline 
group
Allain et al. (1993)
Double-blind RCT, 800 patients 
(DATATOP—final report)
10 mg selegiline vs. placebo 9 months delay in the need of initiation 
of levodopa therapy
Parkinson Study Group (1993)
Double-blind RCT, 20 patients 10 mg selegiline vs. placebo Improved motor scores after 3 weeks in 
the selegiline group
Mally et al. (1995)
Open label continuation of DATATOP, 
310 patients
10 mg selegiline No difference in benefit of early and 
late start of selegiline
Parkinson Study Group (1996)
Double-blind RCT, 157 patients 10 mg selegiline vs. placebo 4 months delay in the need of initiation 
of levodopa therapy.
Improved motor scores were main-
tained after 2-month washout
Palhagen et al. (1998)
Double-blind RCT, 292 patients 10 mg selegiline vs. placebo
(dose was escalated over 
6 weeks)
Improved motor scores after 12 weeks 
in the selegiline group
Mizuno et al. (2017)
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probably due to pharmacokinetic differences (Youdim 
et  al. 2001). A plethora of further preclinical studies 
showed rasagiline possessing a similar profile of ben-
eficial effects as selegiline (Weinreb et al. 2010, 2011).
The effectiveness of rasagiline was evaluated in large 
clinical trials. In the first TEMPO study, its rapid symp-
tomatic effect in early PD was demonstrated (Parkinson 
Study Group 2002). The results of the open-label exten-
sion of this trial indicated that patients on early started 
rasagiline treatment had better UPDRS score compared to 
delayed rasagiline administration during 6.5 years of fol-
low-up, suggesting its neuroprotective property (Hauser 
et al. 2009). These results are similar to those found in 
selegiline studies. The ADAGIO study was designed to 
compare the effect of early vs. delayed start of rasagil-
ine in controlled, randomized trial as well, to explore its 
disease-modifying property. The results, however, are 
contradictory because the extra benefit of early started 
therapy was observed only in case of the lower (1 mg/
day) dose (Olanow et al. 2009). The effectiveness of rasa-
giline in levodopa-treated patients was also proved in the 
PRESTO and LARGO studies (Parkinson Study Group 
2005; Rascol et al. 2005; Elmer 2013).
There are some further recently published data on the 
neuroprotective effect of the MAO-B inhibitors in PD. 
During 2007–2013, a large clinical study, NET-PD LS1, 
was performed, where the primary goal was to evaluate 
the effect of dietary supplement creatine on the progres-
sion of PD. Analysis of data of 1616 participants with 
mean observation time of 4.1 years revealed that 784 
patients receiving MAO-B inhibitor (either selegiline or 
rasagiline) showed less clinical decline and this benefit 
was proportional to the cumulative duration of MAO-B 
inhibitor use. The effect of selegiline and rasagiline 
Table 2  Clinical trials and retrospective studies evaluating the effect of selegiline combinational therapy in PD
Design, number of patients (study 
name)
Studied daily dose Key findings References
Double-blind RCT, 112 patients 7.5 mg selegiline vs. placebo in com-
bination with levodopa
More improvement after 8 weeks in the 
selegiline group
Takahashi et al. (1994)
Retrospective, 82 patients 10 mg selegiline in combination with 
levodopa vs. levodopa alone
No difference in motor scores after 
1–5 years
Lower levodopa dose needed after 
1–3 years in the selegiline group, no 
difference after 4–5 years
Brannan and Yahr (1995)
Double-blind RCT, 101 patients 10 mg selegiline vs. placebo in 
combination with levodopa and/or 
bromocriptine
Less disease deterioration after 1 year in 
the selegiline group.
Benefit was maintained after 2-month 
washout
Olanow et al. (1995)
Double-blind continuation of Myl-
lyla’s study, 44 patients
10 mg selegiline vs. placebo in com-
bination to levodopa
Lower levodopa dose needed even after 
5 years in the selegiline group
Myllyla et al. (1997)
Double-blind RCT, 163 patients 10 mg selegiline vs. placebo in com-
bination with levodopa
Less disease deterioration after 5 years 
in the selegiline group.
Benefit was maintained after 1-month 
washout
Larsen et al. (1999)
Double-blind RCT, 160 patients 10 mg selegiline vs. placebo in com-
bination with levodopa
About twice longer time to need for 
50% increase in levodopa dose in the 
selegiline group
Przuntek et al. (1999)
Double-blind continuation of 
DATATOP, 368 patients
10 mg selegiline vs. placebo in com-
bination with levodopa
Less wearing-off, freezing of gait and 
on–off fluctuation and more dyskine-
sia in the selegiline group
Shoulson et al. (2002)
Double-blind continuation of Pal-
hagen’s study, 140 patients
10 mg selegiline vs. placebo in com-
bination with levodopa
Improved motor scores with 19% lower 
levodopa dose after 5 years in the 
selegiline group
Palhagen et al. (2006)
Retrospective and open label, 691 
patients
10 mg selegiline in combination with 
levodopa started within 5 years of 
disease onset vs. levodopa alone.
4-month open label selegiline treat-
ment initiated in the levodopa alone 
group
Improved motor scores after 10 years in 
the selegiline group.
Motor scores were improved after 
4-month selegiline addition, the late 
started selegiline was less effective 
than the early started one
Mizuno et al. (2010)
Retrospective, 687 patients Effect on disease progression of 
various pharmacotherapies with or 
without selegiline was evaluated
At least 3 years selegiline treatment of 
early PD patients increased the time 
to progression (Hoehn–Yahr stage 
transition)
Zhao et al. (2011)
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was not analyzed separately. These results indicate that 
MAO-B inhibitors may slow the disease progression 
(Hauser et al. 2017). A recent meta-analysis of the avail-
able clinical data confirms the effectiveness of MAO-B 
inhibitors both in monotherapy and in combination with 
levodopa. According to its results, selegiline seems to be 
the most effective MAO-B inhibitor in the combination 
therapy (Binde et al. 2018).
There are several recent reviews discussing the place 
of MAO-B inhibitors in the therapy of PD (Riederer and 
Laux 2011; Fabbrini et al. 2012; Dezsi and Vecsei 2014; 
Marsili et al. 2017; Dezsi and Vecsei 2017; Riederer and 
Muller 2018). More and more data suggest the disease-
modifying effect of selegiline or other MAO-B inhibitor 
therapy, especially when they are started early and used 
long term (Muller and Mohr 2019). However, because of 
their symptoms-improving effect, the mechanisms behind 
the reported clinical benefits could not be unequivocally 
distinguished so far (Olanow 2009; Teo and Ho 2013).
Selegiline in Alzheimer’s disease
Based on its widely examined neuroprotective property, 
selegiline was also studied as a potential therapeutic tool 
for Alzheimer’s disease. Some smaller early trials indi-
cated benefit on both cognitive and behavioral symptoms 
after 3–6 months of treatment. Good tolerability of the 
drug was also confirmed in these studies (Campi et al. 
1990; Monteverde et al. 1990; Mangoni et al. 1991; Finali 
et al. 1992; Filip and Kolibas 1999). However, there were 
some trials that showed only slight, clinically not relevant 
improvements in cognitive and/or behavioral functions 
(Tariot et al. 1987; Burke et al. 1993). The conclusion 
of the meta-analyses is that selegiline may provide mild 
short-term benefit, but its magnitude is not clinically 
meaningful (Wilcock et al. 2002; Birks and Flicker 2003).
The mild benefit in Alzheimer’s disease and the neuro-
protective activity shown in preclinical experiments initi-
ated the development of new drug candidates including 
multitarget compounds. Molecules containing MAO and 
cholinesterase inhibitory pharmacophores were designed 
and found having neuroprotective activities on various 
in vitro and in vivo animal models (Weinreb et al. 2012; 
Unzeta et al. 2016). However, no clinical data with these 
compounds have been reported so far.
Delivery forms of selegiline
Based on the early clinical data of Birkmayer’s studies, 
selegiline was first licensed in Hungary in 1977 by Chi-
noin Pharmaceuticals under the brand name of  Jumex®. 
At that time, it was recommended for alleviation of on–off 
phenomenon in levodopa-treated PD patients. Some years 
later, it was also approved in the same therapeutic indica-
tion in UK (1982) and in the USA as an orphan drug in 
1989.
After the previously discussed clinical trials, the use 
of selegiline tablets was extended to early monotherapy 
of PD in the European Union in 1993 and in the USA in 
1997. Since then the drug has been marketed worldwide.
After oral administration, selegiline undergoes exten-
sive first pass metabolism and systemic exposure of its 
metabolites is considerably higher than that of the parent 
compound. R-Methamphetamine is its primary metabo-
lite that is partially converted to R-amphetamine. In low 
quantity, desmethylselegiline and selegiline-N-oxide are 
also formed as shown in Fig. 1 (Heinonen et al. 1989; 
Szoko et al. 1999; Tabi et al. 2003; Shin 1997). These 
metabolites are pharmacologically active and their con-
tribution to dopaminergic and neuroprotective effects of 
selegiline was suggested on the basis of extensive preclini-
cal experiments (Szende et al. 2001; Magyar et al. 2004, 
2006, 2010). However, Sandler et al. reported that sub-
stitution of selegiline treatment by its metabolites (mix-
ture of R-methamphetamine and R-amphetamine) resulted 
in loss of clinical effect, suggesting no contribution of 
amphetamines to the clinical benefit in Parkinson’s disease 
(Elsworth et al. 1982; Stern et al. 1983). In clinical tri-
als, selegiline was found to be well tolerated with similar 
side effect profile to that of placebo and no amphetamine-
related adverse events were observed (Shoulson 1992; 
Palhagen et al. 1998; Shoulson et al. 2002; Palhagen et al. 
2006; Mizuno et al. 2017). The weaker psychotropic effect 
and dependence liability of R-amphetamines compared to 
the S-enantiomers were shown in several preclinical stud-
ies supporting the findings of the clinical reports (Nickel 
et al. 1994; Yasar et al. 1993).
To improve its bioavailability, new delivery forms of 
selegiline were also developed. Orally disintegrating tablets 
(ODT) are characterized by rapid drug release into saliva. 
A fraction of the active pharmaceutical ingredient absorbs 
through the buccal mucosa, avoiding thus the first pass 
metabolism and providing fast onset of action. According 
to comparative pharmacokinetic studies of conventional and 
ODT formulations, selegiline plasma exposure of 1.25 mg 
ODT was comparable to that of 10 mg conventional tablet. 
Plasma levels of metabolites were considerably lower in case 
of the ODT preparation (Clarke et al. 2003a). Comparative 
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clinical trial of 1.25–2.5 mg selegiline ODT and 10 mg con-
ventional tablets revealed similar efficacy and safety (Clarke 
et al. 2003b). Based on this and some further clinical data, 
selegiline ODT was approved by FDA in 2006 and EMA in 
2010 as an adjunctive therapy to levodopa in PD. By review-
ing the available clinical data, we concluded that the clinical 
advantage of the clear pharmacokinetic improvement is not 
well justified. However, the patients’ preference, because 
of the convenience of ODT use, especially in patients with 
swallowing difficulties, should be acknowledged (Tabi et al. 
2013).
Another innovative formulation, selegiline transdermal 
system (STS), was developed to avoid first pass metabo-
lism. Using STS, the absolute bioavailability increased to 
73% from 4% observed after oral selegiline administration 
(Azzaro et al. 2007). However, the high and sustained plasma 
concentration of selegiline after STS administration results 
in non-selective inhibition of MAO isoforms in the brain. 
In early clinical trials, high, probably non-selective, dose of 
selegiline was found to have antidepressant activity, but the 
risk of cheese effect hindered its use in this indication (Mann 
et al. 1989; Sunderland et al. 1994). It was also reported that 
even chronic daily oral treatment of parkinsonian patients 
with MAO-B inhibitors reduced plasma MAO-A activity 
by about 70% (Bartl et al. 2014), brain data, however, were 
not available. It was only recently demonstrated that about 
33% inhibition of MAO-A was achieved in human brain after 
28-day treatment with STS (6 mg/day) (Fowler et al. 2015). 
It is in accordance with the results of clinical trials show-
ing its antidepressant effect. Since transdermal absorption 
avoids the gastrointestinal tract, no considerable intestinal 
MAO-A inhibition was expected and was first confirmed in 
an animal study (Mawhinney et al. 2003). Low risk of cheese 
effect was thus supposed.
Short-term placebo-controlled studies of 6 and 8 weeks in 
adult patients with major depressive disorder demonstrated 
statistically significant antidepressant activity of STS com-
pared to placebo. The safety profile of the active compound 
was similar to that of placebo except for application-site 
reactions (Bodkin and Amsterdam 2002; Amsterdam 2003; 
Feiger et al. 2006). There was no hypertensive effect (cheese 
effect) observed with even consuming tyramine-enriched 
diet (Blob et al. 2007). The long-term effectiveness of STS 
was also demonstrated for prevention of relapse in those 
major depressive patients who initially responded to the 
preparation. In the STS group, less patients experienced 
relapse and the time till relapse was also longer compared to 
placebo (Amsterdam and Bodkin 2006). One 12-week study 
conducted on adolescents, however, failed to show its superi-
ority to placebo likely due to the high placebo response rate 
(DelBello et al. 2014). STS has FDA approval from 2006 for 
the treatment of major depressive disorder in adults.
Transdermal selegiline was also studied for alleviation of 
nicotine and cocaine dependence. As it increases dopamine 
Fig. 1  Scheme of metabolic 
transformation of selegiline. 
The thick arrow indicates the 
main metabolic step (the forma-
tion of R-methamphetamine)
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level in the brain, it was supposed it might reduce craving. 
Previously in a smaller trial adding oral selegiline to nico-
tine patch doubled the 52-week continuous abstinence rate, 
although the difference was not significant. The need of 
nicotine replacement in the selegiline group was mitigated, 
probably due to reduced craving (Biberman et al. 2003). 
However, in placebo-controlled trials STS failed to improve 
the effectiveness of cognitive behavior intervention in smok-
ing abstinence (Killen et al. 2010; Kahn et al. 2012). In case 
of cocaine dependence, although preliminary data were 
promising the controlled clinical trial with STS also failed 
to show significant effect compared to placebo (Elkashef 
et al. 2006).
Future perspectives
After more than half a century history of the first selective 
MAO-B inhibitor selegiline and its almost 40-year use in 
the treatment of PD, there is still a continuous interest in 
studying the unexplored activities of selegiline and other 
MAO inhibitors.
Promising cardio-metabolic effects of selegiline in animal 
studies were reported by several research groups. Selegiline 
showed antioxidant activity and reduced the fat accumula-
tion in the liver of rats on lipid-rich diet (Bekesi et al. 2012). 
It also improved the metabolism and inflammation in adi-
pose tissue of high-fat, high-sucrose diet-fed rats (Nagy et al. 
2018). Its cytoprotective effect was shown in a rabbit model 
of chronic heart failure by reducing plasma norepinephrine, 
cardiac oxidative stress and myocyte apoptosis (Qin et al. 
2003). MAO-B was also identified as a source of oxidative 
stress in the vasculature, especially in diabetes (Sturza et al. 
2015). MAO-B inhibition by selegiline improved vascular 
function of human mammary arteries in patients with coro-
nary heart disease regardless of the presence of diabetes 
(Lighezan et al. 2016). Alleviation of vascular hyperper-
meability by selegiline was also demonstrated after hem-
orrhagic shock (Tharakan et al. 2010) and thermal injury 
(Whaley et al. 2009).
Potential anticancer activity of MAO inhibitors was 
also suggested. Overexpression of MAO in various cancer 
cells was reported and inhibition of the enzyme resulted in 
antiproliferative effect (Shih 2018; Gaur et al. 2019). Most 
data come from in vitro experiments, but phenelzine, a non-
selective MAO inhibitor, is already in a phase II clinical 
trial for treatment of non-metastatic recurrent prostate can-
cer [ClinicalTrials.gov Identifier: NCT02217709], suggest-
ing the clinical relevance of the anticancer activity of MAO 
inhibitors. High-dose selegiline itself was reported to exert 
cytotoxic effects on various cancer cell lines in vitro. Milli-
molar concentration of selegiline was shown to induce apop-
totic cell death in melanoma cell line (Szende et al. 2000) 
and in acute myelogenous leukemia cells by inhibition of the 
mitochondrial respiration (Ryu et al. 2018). These very high 
concentrations, however, may suggest MAO-independent 
mechanisms that remain to be explored.
The several distinct pharmacological activities observed 
in in vitro and in animal experiments are really interesting, 
but still far from clinical relevance. The diversity of these 
effects may indicate either not yet characterized multiple 
functions of MAO enzyme protein or other targets of MAO 
inhibitor compounds.
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